Item 8.01 Other Events Cure of Nasdaq Bid Price Deficiency On August 17, 2026, Lexaria Bioscience Corp. (the “Company”) received a letter from the Hearings Advisor of The Nasdaq Stock Market (“Nasdaq”) advising that the Nasdaq Listings Qualifications Staff had confirmed that the Company had regained compliance with the bid price requirement in Nasdaq Listing Rule 5550(a)(2).…
Filed Aug 17, 2026Accepted Aug 17, 2026, 12:37 PM EDTCIK 1348362Accession 0001640334-26-001384
Lexaria is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) using our patented DehydraTECHTM drug delivery technology. DehydraTECH combines APIs with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events
Cure of Nasdaq Bid Price Deficiency
On August 17, 2026, Lexaria Bioscience Corp. (the “Company”) received a letter from the Hearings Advisor of The Nasdaq Stock Market (“Nasdaq”) advising that the Nasdaq Listings Qualifications Staff had confirmed that the Company had regained compliance with the bid price requirement in Nasdaq Listing Rule 5550(a)(2). Consequently, the previously requested hearing has been cancelled and the Company’s Common Stock will continue to be listed and trading on The Nasdaq Capital Market.